Resolution of organ dysfunction as a predictor of long-term survival in necrotizing soft tissue infections: Analysis of the AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections trial and a retrospective claims database-linked chart study.
Adult
Aged
CD28 Antigens
/ administration & dosage
Databases, Factual
Debridement
/ methods
Double-Blind Method
Fasciitis, Necrotizing
/ complications
Female
Humans
Male
Middle Aged
Multiple Organ Failure
/ epidemiology
Organ Dysfunction Scores
Prognosis
Retrospective Studies
Soft Tissue Infections
/ complications
Survival Analysis
Journal
The journal of trauma and acute care surgery
ISSN: 2163-0763
Titre abrégé: J Trauma Acute Care Surg
Pays: United States
ID NLM: 101570622
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
pubmed:
3
4
2021
medline:
23
9
2021
entrez:
2
4
2021
Statut:
ppublish
Résumé
Necrotizing soft tissue infections (NSTIs) are an acute surgical condition with high morbidity and mortality. Timely identification, resuscitation, and aggressive surgical management have significantly decreased inpatient mortality. However, reduced inpatient mortality has shifted the burden of disease to long-term mortality associated with persistent organ dysfunction. We performed a combined analysis of NSTI patients from the AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections randomized-controlled interventional trial (ATB-202) and comprehensive administrative database (ATB-204) to determine the association of persistent organ dysfunction on inpatient and long-term outcomes. Persistent organ dysfunction was defined as a modified Sequential Organ Failure Assessment (mSOFA) score of 2 or greater at Day 14 (D14) after NSTI diagnosis, and resolution of organ dysfunction defined as mSOFA score of 1 or less. The analysis included 506 hospitalized NSTI patients requiring surgical debridement, including 247 from ATB-202, and 259 from ATB-204. In both study cohorts, age and comorbidity burden were higher in the D14 mSOFA ≥2 group. Patients with D14 mSOFA score of 1 or less had significantly lower 90-day mortality than those with mSOFA score of 2 or higher in both ATB-202 (2.4% vs. 21.5%; p < 0.001) and ATB-204 (6% vs. 16%: p = 0.008) studies. In addition, in an adjusted covariate analysis of the combined study data sets D14 mSOFA score of 1 or lesss was an independent predictor of lower 90-day mortality (odds ratio, 0.26; 95% confidence interval, 0.13-0.53; p = 0.001). In both studies, D14 mSOFA score of 1 or less was associated with more favorable discharge status and decreased resource utilization. For patients with NSTI undergoing surgical management, persistent organ dysfunction at 14 days, strongly predicts higher resource utilization, poor discharge disposition, and higher long-term mortality. Promoting the resolution of acute organ dysfunction after NSTI should be considered as a target for investigational therapies to improve long-term outcomes after NSTI. Prognostic/epidemiology study, level III.
Sections du résumé
BACKGROUND
Necrotizing soft tissue infections (NSTIs) are an acute surgical condition with high morbidity and mortality. Timely identification, resuscitation, and aggressive surgical management have significantly decreased inpatient mortality. However, reduced inpatient mortality has shifted the burden of disease to long-term mortality associated with persistent organ dysfunction.
METHODS
We performed a combined analysis of NSTI patients from the AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections randomized-controlled interventional trial (ATB-202) and comprehensive administrative database (ATB-204) to determine the association of persistent organ dysfunction on inpatient and long-term outcomes. Persistent organ dysfunction was defined as a modified Sequential Organ Failure Assessment (mSOFA) score of 2 or greater at Day 14 (D14) after NSTI diagnosis, and resolution of organ dysfunction defined as mSOFA score of 1 or less.
RESULTS
The analysis included 506 hospitalized NSTI patients requiring surgical debridement, including 247 from ATB-202, and 259 from ATB-204. In both study cohorts, age and comorbidity burden were higher in the D14 mSOFA ≥2 group. Patients with D14 mSOFA score of 1 or less had significantly lower 90-day mortality than those with mSOFA score of 2 or higher in both ATB-202 (2.4% vs. 21.5%; p < 0.001) and ATB-204 (6% vs. 16%: p = 0.008) studies. In addition, in an adjusted covariate analysis of the combined study data sets D14 mSOFA score of 1 or lesss was an independent predictor of lower 90-day mortality (odds ratio, 0.26; 95% confidence interval, 0.13-0.53; p = 0.001). In both studies, D14 mSOFA score of 1 or less was associated with more favorable discharge status and decreased resource utilization.
CONCLUSION
For patients with NSTI undergoing surgical management, persistent organ dysfunction at 14 days, strongly predicts higher resource utilization, poor discharge disposition, and higher long-term mortality. Promoting the resolution of acute organ dysfunction after NSTI should be considered as a target for investigational therapies to improve long-term outcomes after NSTI.
LEVEL OF EVIDENCE
Prognostic/epidemiology study, level III.
Identifiants
pubmed: 33797490
doi: 10.1097/TA.0000000000003183
pii: 01586154-202108000-00019
doi:
Substances chimiques
CD28 Antigens
0
AB103
U00J02UY29
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
384-392Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis . 2007;44(5):705–710.
Anaya DA, Bulger EM, Kwon YS, Kao LS, Evans H, Nathens AB. Predicting death in necrotizing soft tissue infections: a clinical score. Surg Infect . 2009;10(6):517–522.
Cocanour CS, Chang P, Huston JM, Adams CA Jr., Diaz JJ, Wessel CB, Falcione BA, Bauza GM, Forsythe RA, Rosengart MR. Management and novel adjuncts of necrotizing soft tissue infections. Surg Infect . 2017;18(3):250–272.
May AK, Talisa VB, Wilfret DA, Bulger E, Dankner W, Bernard A, Yende S. Estimating the impact of necrotizing soft tissue infections in the United States: incidence and re-admissions. Surg Infect . 2020.
Young MH, Aronoff DM, Engleberg NC. Necrotizing fasciitis: pathogenesis and treatment. Expert Rev Anti-Infect Ther . 2005;3(2):279–294.
Bulger EM, May A, Bernard A, et al. Impact and progression of organ dysfunction in patients with necrotizing soft tissue infections: a multicenter study. Surg Infect . 2015;16(6):694–701.
May AK, Stafford RE, Bulger EM, Heffernan D, Guillamondegui O, Bochicchio G, Eachempati SR; Surgical Infection Society. Treatment of complicated skin and soft tissue infections. Surg Infect . 2009;10(5):467–499.
Gunter OL, Guillamondegui OD, May AK, Diaz JJ. Outcome of necrotizing skin and soft tissue infections. Surg Infect . 2008;9(4):443–450.
Bernal NP, Latenser BA, Born JM, Liao J. Trends in 393 necrotizing acute soft tissue infection patients 2000–2008. Burns . 2012;38(2):252–260.
Pakula AM, Kapadia R, Freeman B, Skinner RA. A 3-year experience with necrotizing fasciitis: favorable outcomes despite operative delays in a busy acute care hospital. Am Surg . 2012;78(10):1059–1062.
Okoye O, Talving P, Lam L, Smith J, Teixeira PG, Inaba K, Koronakis N, Demetriades D. Timing of redebridement after initial source control impacts survival in necrotizing soft tissue infection. Am Surg . 2013;79(10):1081–1085.
Soltani AM, Best MJ, Francis CS, Allan BJ, Askari M, Panthaki ZJ. Trends in the incidence and treatment of necrotizing soft tissue infections: an analysis of the National Hospital Discharge Survey. J Burn Care Res . 2014;35(5):449–454.
Brakenridge SC, Efron PA, Cox MC, et al. Current epidemiology of surgical sepsis: discordance between inpatient mortality and 1-year outcomes. Ann Surg . 2019;270(3):502–510.
Gardner AK, Ghita GL, Wang Z, et al. The development of chronic critical illness determines physical function, quality of life, and long-term survival among early survivors of sepsis in surgical ICUs. Crit Care Med . 2019;47(4):566–573.
Pham TN, Moore ML, Costa BA, Cuschieri J, Klein MB. Assessment of functional limitation after necrotizing soft tissue infection. J Burn Care Res . 2009;30(2):301–306.
McGillicuddy EA, Lischuk AW, Schuster KM, Kaplan LJ, Maung A, Lui FY, Bokhari SA, Davis KA. Development of a computed tomography-based scoring system for necrotizing soft-tissue infections. J Trauma . 2011;70(4):894–899.
Lungstras-Bufler K, Bufler P, Abdullah R, Rutherford C, Endres S, Abraham E, Dinarello CA, Rodriguez RM. High cytokine levels at admission are associated with fatal outcome in patients with necrotizing fasciitis. Eur Cytokine Netw . 2004;15(2):135–138.
Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine. Intensive Care Med . 1996;22(7):707–710.
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA . 2016;315(8):801–810.
Stortz JA, Mira JC, Raymond SL, et al. Benchmarking clinical outcomes and the immunocatabolic phenotype of chronic critical illness after sepsis in surgical intensive care unit patients. J Trauma Acute Care Surg . 2018;84(2):342–349.
Ramachandran G, Tulapurkar ME, Harris KM, et al. A peptide antagonist of CD28 signaling attenuates toxic shock and necrotizing soft-tissue infection induced by streptococcus pyogenes. J Infect Dis . 2013;207(12):1869–1877.
Bulger EM, Maier RV, Sperry J, et al. A novel drug for treatment of necrotizing soft-tissue infections: a randomized clinical trial. JAMA Surg . 2014;149(6):528–536.
Bulger EM, May AK, Robinson BRH, et al; ACCUTE Study Investigators. A novel immune modulator for patients with necrotizing soft tissue infections (NSTI): results of a multicenter, phase 3 randomized controlled trial of reltecimod (AB 103). Ann Surg . 2020;272:469–478.
Bulger EM, May A, Dankner W, Maislin G, Robinson B, Shirvan A. Validation of a clinical trial composite endpoint for patients with necrotizing soft tissue infections. J Trauma Acute Care Surg . 2017;83(4):622–627.
Hansen MB. Biomarkers of Necrotising Soft Tissue Infections Aspects of the Innate Immune Response. Dan Med J . 2017;64(7):B5389.
Schwarze ML, Brasel KJ, Mosenthal AC. Beyond 30-day mortality: aligning surgical quality with outcomes that patients value. JAMA Surg . 2014;149(7):631–632.
Oud L. Determinants of home discharge among survivors of necrotizing fasciitis: a population-level analysis. J Clin Med Res . 2016;8(7):537–543.
Light TD, Choi KC, Thomsen TA, et al. Long-term outcomes of patients with necrotizing fasciitis. J Burn Care Res . 2010;31(1):93–99.
Hakkarainen TW, Burkette Ikebata N, Bulger E, Evans HL. Moving beyond survival as a measure of success: understanding the patient experience of necrotizing soft-tissue infections. J Surg Res . 2014;192(1):143–149.
Gentile LF, Cuenca AG, Efron PA, Ang D, Bihorac A, McKinley BA, Moldawer LL, Moore FA. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg . 2012;72(6):1491–1501.
Elliott D, Davidson JE, Harvey MA, et al. Exploring the scope of post-intensive care syndrome therapy and care: engagement of non-critical care providers and survivors in a second stakeholders meeting. Crit Care Med . 2014;42(12):2518–2526.
Kress JP, Hall JB. ICU-acquired weakness and recovery from critical illness. N Engl J Med . 2014;371(3):287–288.
Vanzant EL, Lopez CM, Ozrazgat-Baslanti T, et al. Persistent inflammation, immunosuppression, and catabolism syndrome after severe blunt trauma. J Trauma Acute Care Surg . 2014;76(1):21–29; discussion 9-30.
Mira JC, Gentile LF, Mathias BJ, Efron PA, Brakenridge SC, Mohr AM, Moore FA, Moldawer LL. Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome. Crit Care Med . 2017;45(2):253–262.
Hawkins RB, Raymond SL, Stortz JA, et al. Chronic critical illness and the persistent inflammation, immunosuppression, and catabolism syndrome. Front Immunol . 2018;9:1511.
Moore LJ, McKinley BA, Turner KL, Todd SR, Sucher JF, Valdivia A, Sailors RM, Kao LS, Moore FA. The epidemiology of sepsis in general surgery patients. J Trauma . 2011;70(3):672–680.
Davidson GH, Hamlat CA, Rivara FP, Koepsell TD, Jurkovich GJ, Arbabi S. Long-term survival of adult trauma patients. JAMA . 2011;305(10):1001–1007.
Chao PW, Shih CJ, Lee YJ, et al. Association of postdischarge rehabilitation with mortality in intensive care unit survivors of sepsis. Am J Respir Crit Care Med . 2014;190(9):1003–1011.
Rahmel T, Schmitz S, Nowak H, Schepanek K, Bergmann L, Halberstadt P, Horter S, Peters J, Adamzik M. Long-term mortality and outcome in hospital survivors of septic shock, sepsis, and severe infections: the importance of aftercare. PLoS One . 2020;15(2):e0228952.
Cox MC, Brakenridge SC, Stortz JA, Hawkins RB, Darden DB, Ghita GL, Mohr AM, Moldawer LL, Efron PA, Moore FA. Abdominal sepsis patients have a high incidence of chronic critical illness with dismal long-term outcomes. Am J Surg . 2020;220(6):1467–1474.
Mills MK, Faraklas I, Davis C, Stoddard GJ, Saffle J. Outcomes from treatment of necrotizing soft-tissue infections: results from the National Surgical Quality Improvement Program database. Am J Surg . 2010;200(6):790–796; discussion 6-7.